IP Library › Granted Patent US 6,927,044
Granted Patent B2
US 6,927,044 · App. 10/282,162 · Granted Aug 9, 2005

IL-1 receptor based cytokine traps

Assignee: Regeneron Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,927,044
App. No.
10/282,162
Granted
Aug 9, 2005
Kind
B2
Abstract

Fusion polypeptides capable of binding interleukin-1 (IL-1) to form a nonfunctional complex are provided and nucleic acid molecules encoding the fusion polypeptides. The fusion ploypeptides form dimers to function as IL-1 antagonists.

Claims (30)

1. A recombinant nucleic acid molecule encoding a fusion polypeptide which forms a multimer capable of binding interleukin-1 (IL-1) to form a nonfunctional complex, wherein the nucleic acid molecule comprises SEQ ID NO:33.

2. A fusion polypeptide encoded by the nucleic acid molecule of claim 1 .

3. The nucleic acid molecule of claim 1 , wherein the fusion polypeptide comprises the amino acid sequence of SEQ ID NO:34.

4. A recombinant nucleic acid molecule encoding a fusion polypeptide which forms a multimer capable of binding interleukin-1 (IL-1) to form a nonfunctional complex, wherein the nucleic acid molecule comprises SEQ ID NO:35.

5. A fusion polypeptide encoded by the nucleic acid molecule of claim 4 .

6. A nucleic acid molecule encoding a fusion polypeptide comprising the amino acid sequence of SEQ ID NO:36.

7. A recombinant nucleic acid molecule encoding a fusion polypeptide which forms a multimer capable of binding interleukin-1 (IL-1) to form a nonfunctional complex, wherein the nucleic acid molecule comprises SEQ ID NO:37.

8. A fusion polypeptide encoded by the nucleic acid molecule of claim 7 .

9. The A nucleic acid molecule encoding a fusion polypeptide comprising the amino acid sequence of SEQ ID NO:38.

10. The nucleic acid of claim 1 , 4 , or 7 , wherein nucleotide 1979 is changed from A to C.

11. A fusion polypeptide encoded by the nucleic acid molecule of claim 10 .

12. A recombinant nucleic acid molecule encoding a fusion polypeptide which forms a multimer capable of binding interleukin-1 (IL-1) to form a nonfunctional complex, wherein the nucleic acid molecule comprises SEQ ID NO:39.

13. A fusion polypeptide encoded by the nucleic acid molecule of claim 12 .

14. A nucleic acid molecule encoding a fusion polypeptide comprising the amino acid sequence of SEQ ID NO:40.

15. A recombinant nucleic acid molecule encoding a fusion polypeptide which forms a multimer capable of binding interleukin-1 (IL-1) to form a nonfunctional complex, wherein the nucleic acid molecule comprises SEQ ID NO:41.

16. A fusion polypeptide encoded by the nucleic acid molecule of claim 15 .

17. A nucleic acid molecule encoding a fusion polypeptide comprising the amino acid sequence of SEQ ID NO:42.

18. A recombinant nucleic acid molecule encoding a fusion polypeptide which forms a multimer capable of binding interleukin-1 (IL-1) to form a nonfunctional complex, wherein the nucleic acid molecule comprises SEQ ID NO:43.

19. A fusion polypeptide encoded by the nucleic acid molecule of claim 18 .

20. A nucleic acid molecule encoding a fusion polypeptide comprising the amino acid sequence of SEQ ID NO:44.

21. The nucleic acid of claim 12 , 15 , or 18 , wherein nucleotide 1043 is changed from A to C.

22. A fusion polypeptide encoded by the nucleic acid molecule of claim 21 .

23. A composition capable of binding IL-1 to form a non-functional complex comprising a multimer of the fusion polypeptide of any of claims 2 , 5 , 8 , 11 , 13 , 16 , 19 , or 22 .

24. The composition of claim 23 , wherein the multimer is a dimer.

25. A vector comprising the nucleic acid molecule of any of claims 1 , 4 , 7 , 10 , 12 , 15 , 18 , and 21 .

26. An expression vector comprising the nucleic acid molecule of any of claims 1 , 4 , 7 , 10 , 12 , 15 , 18 , and 21 operatively linked to an expression control sequence.

27. A host-vector system for the production of a fusion polypeptide, comprising the expression vector of claim 26 in a suitable host cell.

28. The host-vector system of claim 27 , wherein the suitable host cell is a bacterial cell, yeast cell, insect cell, or mammalian cell.

29. A method of producing a fusion polypeptide that comprises growing cells of the host-vector system of claim 27 , under conditions permitting production of the fusion polypeptide and recovering the fusion polypeptide so produced.

30. The host-vector system of claim 28 , wherein the suitable host cell is a CHO cell.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 5, 2003
From: STAHL, NEIL; YANCOPOULOS, GEORGE D.
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 014458/0202 →
Continuity (4)
Continuation In Part 0978783500
Continuation 0931394200 · May 19, 1999
Provisional Application 6010185800 · Sep 25, 1998
Related Publication 20030143697A1 · Jul 31, 2003